EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials

Dinesh Stanislaus, Christopher J Bowman iD, Kimberly C Brannen iD, Sarah N Campion iD, Laura M Carlson iD, Stephan Chalon iD, Anthony M DeLise iD, Claudia Demarta-Gatsi iD, Brian P Enright, Wendy Halpern iD, Shermaine Mitchell-Ryan, Vicki Sutherland iD und 7 weitere

Birth Defects Research · 2026-06 · 118 (6)

DOI: 10.1002/bdr2.70074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Birth Defects Research, online erschienen am 04.06.2026. Verfasst von Dinesh Stanislaus und 18 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Lactation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically exclude pregnant and breastfeeding populations or require highly effective contraception for women of childbearing potential. Consequently, medications may be used during pregnancy or lactation despite limited supporting evidence, which can lead to treatment interruption, suboptimal dosing, and increased maternal or fetal risk. Emerging regulatory guidance, including draft ICH Guideline on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials (E21), highlights the ethical and clinical need to generate data directly in these populations.

Methods

This paper evaluates the current regulatory framework for nonclinical studies described in ICH S5(R3) and M3(R2) and examines how these studies can support the enrollment of pregnant and breastfeeding individuals in clinical trials. It proposes pragmatic adaptations to align nonclinical testing with the anticipated clinical context of use and considers the role of new approach methodologies (NAMs) and alternative study designs.

Results

Potential DART strategies are described that could enable the inclusion of pregnant individuals in clinical trials based on factors such as dosing duration, route of administration, and study type (e.g., pharmacokinetic studies). The paper also considers the use of NAMs, including physiologically based pharmacokinetic modeling and in vitro assays, as well as alternative study designs such as preliminary pre‐ and postnatal development or extended embryo–fetal development studies. Approaches to inform studies in breastfeeding populations, including milk–plasma ratio modeling and translation from nonclinical data, are also discussed.

Conclusions

These approaches support a shift from routine exclusion toward proactive and ethical inclusion of pregnant and breastfeeding individuals in clinical research, helping address longstanding evidence gaps and improving therapeutic decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicLactationAnimalsFemaleHumansPregnancyBreast FeedingDrug Development

Stichwörter der Autor:innen

lactationpreclinicalpregnancy

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • Pfizer Inc., Groton, Connecticut, USA.
  • Merck & Co. Inc., Rahway, New Jersey, USA.
  • Office of Research and Development, US EPA, Durham, North Carolina, USA.
  • Medicines for Malaria Venture (MMV), Geneva, Switzerland.
  • Novartis Pharmaceuticals Company, East Hanover, New Jersey, USA.

ORCID-Profile: Christopher J Bowman, Kimberly C Brannen, Sarah N Campion, Laura M Carlson, Stephan Chalon, Anthony M DeLise, Claudia Demarta-Gatsi, Wendy Halpern, Vicki Sutherland, Steven Van Cruchten, Ronald L Wange, Connie L Chen

Zitieren

APA

Stanislaus, D., Bowman, C. J., Brannen, K. C., Campion, S. N., Carlson, L. M., Chalon, S., DeLise, A. M., Demarta-Gatsi, C., Enright, B. P., Halpern, W., Mitchell-Ryan, S., Sutherland, V., Thacker, K., Thompson, K., Tornesi, B., Van Cruchten, S., Wange, R. L., White, T., & Chen, C. L. (2026). Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials. Birth Defects Research, 118(6). https://doi.org/10.1002/bdr2.70074

Vancouver

Stanislaus D, Bowman CJ, Brannen KC, Campion SN, Carlson LM, Chalon S, et al. Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials. Birth Defects Research. 2026;118(6). doi:10.1002/bdr2.70074

BibTeX
@article{Stanislaus2026,
  author = {Stanislaus, Dinesh and Bowman, Christopher J and Brannen, Kimberly C and Campion, Sarah N and Carlson, Laura M and Chalon, Stephan and DeLise, Anthony M and Demarta-Gatsi, Claudia and Enright, Brian P and Halpern, Wendy and Mitchell-Ryan, Shermaine and Sutherland, Vicki and Thacker, Karen and Thompson, Kary and Tornesi, Belen and Van Cruchten, Steven and Wange, Ronald L and White, Tacey and Chen, Connie L},
  title = {Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials},
  journal = {Birth Defects Research},
  year = {2026},
  volume = {118},
  number = {6},
  doi = {10.1002/bdr2.70074}
}
Kostenlos starten →